<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01401088</url>
  </required_header>
  <id_info>
    <org_study_id>1PN1011049</org_study_id>
    <nct_id>NCT01401088</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Efficacy of Glaucoma Shunt (Aurolab Artificial Drainage Implant) in Refractory Glaucoma</brief_title>
  <acronym>AADI</acronym>
  <official_title>Evaluation of Safety and Efficacy of Glaucoma Shunt (Aurolab Artificial Drainage Implant) in Refractory Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurolab</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aurolab</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Aurolab Artificial
      Drainage Implant (AADI) on intraocular pressure reduction in patients with refractory
      glaucoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aurolab Artificial Drainage Implant is a non resistant tube device based on Baerveldt
      implant. It reduces intra ocular pressure by draining aqueous from anterior chamber into
      sub-conjunctival space formed around base of the implant. Reduction of intraocular pressure
      prevents further damage to optic nerve and functional visual field loss in advanced
      refractory glaucoma.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intra Ocular Pressure (IOP)</measure>
    <time_frame>One year</time_frame>
    <description>Mean Intraocular pressure (IOP) reduction from pre operative IOP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success rate</measure>
    <time_frame>one year</time_frame>
    <description>Success rate (defined as Inraocular pressure (IOP) of 5mmHg to 20 mmHg and at least a 20% reduction in IOP without visually devastating complications or additional glaucoma surgery)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events as a measure of safety</measure>
    <time_frame>one year</time_frame>
    <description>to assess the incidence of post operative adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Artificial drainage implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aurolab Artificial Drainage Implant (AADI) on intraocular pressure reduction will be implanted in patients with refractory glaucoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Artificial drainage implant</intervention_name>
    <description>Artificial drainage implant is used for intra ocular pressure reduction in patient with refractory glaucoma</description>
    <arm_group_label>Artificial drainage implant</arm_group_label>
    <other_name>AADI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Significant optic nerve damage and visual field loss due to glaucoma in eligible eyes

          -  Eligible eyes is considered at high risk of failure/complication following
             conventional filtering surgery

          -  Eyes with uncontrolled glaucoma with prior history of Filtering surgery/Uveitic/
             Neovascular/Developmental glaucomas

          -  IOPâ‰¥18 mm of Hg with or without anti glaucoma medications

          -  If taking glaucoma medications, stable dose for 6 weeks

        Exclusion Criteria:

          -  Age&lt;18 years

          -  Eyes with uncontrolled glaucoma expected to have favorable post-operative outcome by
             conventional trabeculectomy

          -  Corneal abnormalities that would preclude accurate IOP readings

          -  Uncontrolled systemic diseases

          -  Endothelial cell count&lt;1800cells/mm

          -  Any other active ocular disease,(active uveitis, ocular infection)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Prashanth Ranganath, MBBS., MS.,</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aravind Eye Hospital, Madurai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr. Prashanth Ranganath, MBBS., MS.,</last_name>
    <phone>+91 452 4356100</phone>
    <phone_ext>118</phone_ext>
    <email>loweriop@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mr.S.Karthi Kumar, M.Pahrmacy</last_name>
    <phone>+91 452 4356100</phone>
    <phone_ext>229</phone_ext>
    <email>crd@aurolab.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aravind Eye Hospital</name>
      <address>
        <city>Madurai</city>
        <state>Tamilnadu</state>
        <zip>625020</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mr. S.Karthi Kumar, M. Pharmacy</last_name>
      <phone>+91 452 3096100</phone>
      <phone_ext>229</phone_ext>
      <email>crd@aurolab.com</email>
    </contact>
    <contact_backup>
      <last_name>Ms. Sophia , M.Sc</last_name>
      <phone>+91 452 4356100</phone>
      <phone_ext>364</phone_ext>
      <email>clinicaltrials@aravind.org</email>
    </contact_backup>
    <investigator>
      <last_name>Dr. Prashanth Ranganath, MBBS., MS.,</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2011</study_first_submitted>
  <study_first_submitted_qc>July 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2011</study_first_posted>
  <last_update_submitted>January 2, 2013</last_update_submitted>
  <last_update_submitted_qc>January 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>patient with refractory glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

